Suppr超能文献

原发性胆汁性肝硬化患者的血清β2-微球蛋白水平

Serum beta 2-microglobulin levels in primary biliary cirrhosis.

作者信息

Nyberg A, Lööf L, Hällgren R

出版信息

Hepatology. 1985 Mar-Apr;5(2):282-5. doi: 10.1002/hep.1840050222.

Abstract

Serum beta 2-microglobulin (beta 2 mu) was determined in 44 patients with primary biliary cirrhosis (PBC) and in 63 patients with other liver disorders. beta 2 mu levels were elevated in PBC when compared with chronic persistent hepatitis, primary sclerosing cholangitis and noncirrhotic alcohol liver disease, but not in comparison with chronic active hepatitis and alcoholic liver cirrhosis. With the exception of chronic persistent hepatitis, all liver disorders had significantly increased serum concentrations of beta 2 mu when compared with controls. A significant correlation between beta 2 mu and erythrocyte sedimentation rate (p less than 0.001) and beta 2 mu and serum IgG (p less than 0.05) was found in PBC. No significant difference in beta 2 mu levels was noted when PBC patients with early and late histopathological changes were compared. D-penicillamine treatment significantly (p less than 0.01) but transiently reduced beta 2 mu levels in PBC; this may reflect the presumed immunosuppressive action of this drug.

摘要

对44例原发性胆汁性肝硬化(PBC)患者和63例其他肝脏疾病患者测定了血清β2-微球蛋白(β2μ)。与慢性持续性肝炎、原发性硬化性胆管炎和非肝硬化酒精性肝病相比,PBC患者的β2μ水平升高,但与慢性活动性肝炎和酒精性肝硬化相比则未升高。与对照组相比,除慢性持续性肝炎外,所有肝脏疾病患者的血清β2μ浓度均显著升高。在PBC患者中,发现β2μ与红细胞沉降率(p<0.001)以及β2μ与血清IgG(p<0.05)之间存在显著相关性。比较组织病理学改变早期和晚期的PBC患者时,β2μ水平未发现显著差异。青霉胺治疗可使PBC患者的β2μ水平显著(p<0.01)但短暂降低;这可能反映了该药物的假定免疫抑制作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验